No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Macro and narrative headwinds in biotech valuation
The guest outlined how rising interest rates and capital flight toward AI created a structural downturn in development-stage biotech valuations between 2021 and 2024.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.